Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Basar, Rafet  [Clear All Filters]
2024
Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, et al. Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2024.
Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 B cell tumors: a phase 1/2 trial. Nat Med. 2024.
2023
Dragomir MP, Fuentes-Mattei E, Winkle M, Okubo K, Bayraktar R, Knutsen E, Qdaisat A, Chen M, Li Y, Shimizu M, et al. Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response. J Clin Invest. 2023.
Lui A, Lee J, Thall PF, Daher M, Rezvani K, Basar R. A Bayesian feature allocation model for identifying cell subpopulations using CyTOF data. J R Stat Soc Ser C Appl Stat. 2023;72(3):718-738.
Nieto Y, Banerjee P, Kaur I, Kim KHee, Fang D, Thall PF, Griffin L, Barnett M, Basar R, Hosing C, et al. EX VIVO-EXPANDED CORD BLOOD NK CELLS COMBINED WITH RITUXIMAB AND HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS SCT FOR B-NHL. Transplant Cell Ther. 2023.
Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, et al. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv. 2023;9(30):eadd6997.
2022
Fix SM, Forget M-A, Sakellariou-Thompson D, Wang Y, Griffiths TM, Lee M, Haymaker CL, Dominguez ALucía, Basar R, Reyes C, et al. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling. J Immunother Cancer. 2022;10(7).
2021
Basar R, Uprety N, Ensley E, Daher M, Klein K, Martínez F, Aung F, Shanley M, Hu B, Gokdemir E, et al. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell Rep. 2021:109432.
Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, et al. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021:JCO2002608.
2020
Miao Q, Wang F, Dou J, Iqbal R, Muftuoglu M, Basar R, Li L, Rezvani K, Chen K. Ab initio Spillover Compensation in CyTOF Data. Cytometry A. 2020.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Kerbauy LNassif, Overman B, Thall P, Kaplan M, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545-553.
2019
Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PProsad, Shaim H, Daher M, Basar R, et al. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv. 2019;3(23):4117-4130.